KR100935904B1 - 항바이러스성 약물의 말레산 단일염 및 이를 함유하는약제학적 조성물 - Google Patents
항바이러스성 약물의 말레산 단일염 및 이를 함유하는약제학적 조성물 Download PDFInfo
- Publication number
- KR100935904B1 KR100935904B1 KR1020080004100A KR20080004100A KR100935904B1 KR 100935904 B1 KR100935904 B1 KR 100935904B1 KR 1020080004100 A KR1020080004100 A KR 1020080004100A KR 20080004100 A KR20080004100 A KR 20080004100A KR 100935904 B1 KR100935904 B1 KR 100935904B1
- Authority
- KR
- South Korea
- Prior art keywords
- maleic acid
- methyl
- salts
- pivalate
- dimethyl
- Prior art date
Links
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 title claims abstract description 53
- 239000011976 maleic acid Substances 0.000 title claims abstract description 53
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 title claims abstract description 53
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 title claims abstract description 52
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 10
- 239000003443 antiviral agent Substances 0.000 title abstract 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims abstract description 25
- -1 {1-[(2-amino-9H-purin-9-yl) methyl] cyclopropyl} oxy Chemical group 0.000 claims abstract description 18
- 229950010765 pivalate Drugs 0.000 claims abstract description 17
- 150000003839 salts Chemical class 0.000 claims description 48
- 239000007787 solid Substances 0.000 claims description 23
- 238000004458 analytical method Methods 0.000 claims description 7
- 239000000203 mixture Substances 0.000 claims description 6
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 4
- 241000700605 Viruses Species 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 150000002689 maleic acids Chemical class 0.000 claims 1
- AQGMJUDZABJUBH-UPHRSURJSA-N (z)-4-chloro-4-oxobut-2-enoic acid Chemical compound OC(=O)\C=C/C(Cl)=O AQGMJUDZABJUBH-UPHRSURJSA-N 0.000 abstract description 2
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical class CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 49
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 36
- 230000000052 comparative effect Effects 0.000 description 21
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 15
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 13
- 239000003814 drug Substances 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 8
- 239000011521 glass Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 5
- 241000700721 Hepatitis B virus Species 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 238000000113 differential scanning calorimetry Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 3
- 150000002688 maleic acid derivatives Chemical class 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 229940098779 methanesulfonic acid Drugs 0.000 description 3
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical class C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000263 cytotoxicity test Toxicity 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- OGVQVRQUMGOQHQ-ODZAUARKSA-N (z)-but-2-enedioic acid;sulfuric acid Chemical compound OS(O)(=O)=O.OC(=O)\C=C/C(O)=O OGVQVRQUMGOQHQ-ODZAUARKSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- AQEFLFZSWDEAIP-UHFFFAOYSA-N di-tert-butyl ether Chemical compound CC(C)(C)OC(C)(C)C AQEFLFZSWDEAIP-UHFFFAOYSA-N 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical class CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 description 1
- 229940011051 isopropyl acetate Drugs 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (7)
- 3-[({1-[(2-아미노-9H-퓨린-9-일)메틸]사이클로프로필}옥시)메틸]-8,8-디메틸-3,7-디옥소-2,4,6-트리옥사-3λ5-포스파논-1-일-피발레이트의 말레산 단일염.
- 제1항에 있어서, 결정성 고체인 것을 특징으로 하는 말레산 단일염.
- 제2항에 있어서, 분말 X선 회절 분석에서 2Θ= 5.6, 12.1, 17.5 및 20.9°의 회절각을 가짐을 특징으로 하는 말레산 단일염.
- 제3항에 있어서, 분말 X선 회절 분석에서 2Θ= 5.6, 10.0, 12.1, 13.1, 17.5, 18.8, 20.9, 22.8, 24,3, 25,1 및 26.5°의 회절각을 가짐을 특징으로 하는 말레산 단일염.
- 제1항 내지 제4항 중 어느 한 항에 따른 말레산 단일염; 및 약제학적으로 허용되는 담체를 포함하는, 바이러스 감염을 예방 또는 치료하기 위한 약제학적 조성물.
- 제5항에 있어서, 바이러스가 HBV 인 것을 특징으로 하는 조성물.
- 제5항에 있어서, 바이러스가 HIV 인 것을 특징으로 하는 조성물.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020070005269 | 2007-01-17 | ||
KR20070005269 | 2007-01-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20080067969A KR20080067969A (ko) | 2008-07-22 |
KR100935904B1 true KR100935904B1 (ko) | 2010-01-07 |
Family
ID=39636116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020080004100A KR100935904B1 (ko) | 2007-01-17 | 2008-01-14 | 항바이러스성 약물의 말레산 단일염 및 이를 함유하는약제학적 조성물 |
Country Status (17)
Country | Link |
---|---|
US (1) | US20090325904A1 (ko) |
EP (1) | EP2124953A4 (ko) |
JP (1) | JP4980431B2 (ko) |
KR (1) | KR100935904B1 (ko) |
CN (1) | CN101616674B (ko) |
AR (1) | AR064915A1 (ko) |
BR (1) | BRPI0806461B8 (ko) |
CA (1) | CA2673510C (ko) |
CL (1) | CL2008000070A1 (ko) |
CO (1) | CO6210809A2 (ko) |
EA (1) | EA015269B1 (ko) |
MX (1) | MX2009006826A (ko) |
MY (1) | MY163479A (ko) |
TW (1) | TWI384986B (ko) |
UA (1) | UA91655C2 (ko) |
WO (1) | WO2008088147A1 (ko) |
ZA (1) | ZA200904378B (ko) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018016795A1 (ko) * | 2016-07-18 | 2018-01-25 | 일동제약주식회사 | 항바이러스성 약물의 오로트산염, 이의 제조 방법 및 상기 염을 포함하는 약제학적 조성물 |
WO2018164458A1 (ko) * | 2017-03-07 | 2018-09-13 | 일동제약주식회사 | 베시포비르 디피복실 또는 이의 약제학적 허용되는 염 함유 과립, 상기 과립을 포함하는 약제학적 조성물 및 이의 제조 방법 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107312039B (zh) | 2012-08-30 | 2019-06-25 | 江苏豪森药业集团有限公司 | 一种替诺福韦前药的制备方法 |
WO2016107833A1 (en) * | 2014-12-31 | 2016-07-07 | F. Hoffmann-La Roche Ag | A novel high-throughput method for quantification of hbv cccdna from cell lysate by real-time pcr |
CN106977548A (zh) * | 2016-01-19 | 2017-07-25 | 四川海思科制药有限公司 | 倍司福韦复合物及其制备方法和用途 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100441638B1 (ko) | 2001-01-19 | 2004-07-23 | 주식회사 엘지생명과학 | 새로운 에이사이클릭 뉴클레오사이드 포스포네이트유도체, 그의 염 및 합성 방법 |
US20060052346A1 (en) | 2004-02-17 | 2006-03-09 | Averett Devron R | Nucleoside phosphonate derivatives useful in the treatment of HIV infections |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2887481A (en) * | 1957-04-29 | 1959-05-19 | Schering Corp | Heterocyclic amides |
US3832460A (en) * | 1971-03-19 | 1974-08-27 | C Kosti | Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue |
DK161312C (da) * | 1982-03-11 | 1991-12-09 | Pfizer | Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden |
NZ243065A (en) * | 1991-06-13 | 1995-07-26 | Lundbeck & Co As H | Piperidine derivatives and pharmaceutical compositions |
WO1994012497A1 (en) * | 1992-11-20 | 1994-06-09 | Taisho Pharmaceutical Co., Ltd. | Heterocyclic compound |
EP0620222A3 (en) * | 1993-04-14 | 1995-04-12 | Lilly Co Eli | Tetrahydro-beta-carbolines. |
US5795909A (en) * | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
US6624138B1 (en) * | 2001-09-27 | 2003-09-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
US7927613B2 (en) * | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
CN1684970A (zh) * | 2002-09-26 | 2005-10-19 | 株式会社Lg生命科学 | (1-膦酰甲氧基-2-烷基环丙基) 甲基核苷衍生物的(+)-反式-异构体、用于制备其立体异构体的方法、及其抗病毒剂的用途 |
WO2004029049A1 (ja) * | 2002-09-30 | 2004-04-08 | Yamanouchi Pharmaceutical Co., Ltd. | 2-アシルアミノチアゾール誘導体の新規な塩 |
US7167750B2 (en) * | 2003-02-03 | 2007-01-23 | Enteromedics, Inc. | Obesity treatment with electrically induced vagal down regulation |
DK1670785T3 (da) * | 2003-10-02 | 2010-10-18 | Pharmacia & Upjohn Co Llc | Salte og polymorphe former af en pyrrolsubstitueret indolinonforbindelse |
GB0330002D0 (en) * | 2003-12-24 | 2004-01-28 | Astrazeneca Ab | Quinazoline derivatives |
CA2562627A1 (en) * | 2004-04-26 | 2005-11-10 | Santiago Ini | Preparation of tegaserod and tegaserod maleate |
KR101033290B1 (ko) * | 2004-07-02 | 2011-05-09 | 주식회사 엘지생명과학 | 다이아이소프로필((1-(하이드록시메틸)-사이클로프로필)옥시)메틸포스포네이트의 새로운 제조 방법 |
DE102005034974A1 (de) * | 2005-07-22 | 2007-04-19 | Grünenthal GmbH | Salz von Dimethylaminomethyl-phenyl-cyclohexan und dessen kristalline Formen |
CA2615760A1 (en) * | 2005-08-08 | 2007-02-15 | Pfizer Inc. | Salts and polymorphs of n,2-dimethyl-6-[7-(2-morpholinoethoxy)quinolin-4-yloxy]benzofuran-3-carboxamide |
ATE549317T1 (de) * | 2005-11-08 | 2012-03-15 | Millennium Pharm Inc | Pharmazeutische salze und polymorphe aus n-(5- chloro-2-pyridinyl)-2-ää4- ä(dimethylamino)iminomethylübenzoylüaminoü-5- methoxy-benzamid, einem faktor-xa-hemmer |
US20080161324A1 (en) * | 2006-09-14 | 2008-07-03 | Johansen Lisa M | Compositions and methods for treatment of viral diseases |
MX2009003410A (es) * | 2006-09-29 | 2009-07-17 | Idenix Pharmaceuticals Inc | Fosfoindoles enantiomericamente puros como inhibidores de vih. |
-
2008
- 2008-01-10 CL CL200800070A patent/CL2008000070A1/es unknown
- 2008-01-10 TW TW097100957A patent/TWI384986B/zh active
- 2008-01-11 WO PCT/KR2008/000194 patent/WO2008088147A1/en active Application Filing
- 2008-01-11 JP JP2009546316A patent/JP4980431B2/ja active Active
- 2008-01-11 CA CA2673510A patent/CA2673510C/en active Active
- 2008-01-11 CN CN2008800025393A patent/CN101616674B/zh active Active
- 2008-01-11 MX MX2009006826A patent/MX2009006826A/es active IP Right Grant
- 2008-01-11 EA EA200970690A patent/EA015269B1/ru unknown
- 2008-01-11 BR BRPI0806461A patent/BRPI0806461B8/pt active IP Right Grant
- 2008-01-11 US US12/522,046 patent/US20090325904A1/en not_active Abandoned
- 2008-01-11 EP EP08704733A patent/EP2124953A4/en not_active Withdrawn
- 2008-01-11 MY MYPI20092745A patent/MY163479A/en unknown
- 2008-01-11 UA UAA200907518A patent/UA91655C2/ru unknown
- 2008-01-14 KR KR1020080004100A patent/KR100935904B1/ko active Protection Beyond IP Right Term
- 2008-01-16 AR ARP080100182A patent/AR064915A1/es not_active Application Discontinuation
-
2009
- 2009-06-23 ZA ZA200904378A patent/ZA200904378B/xx unknown
- 2009-07-17 CO CO09074840A patent/CO6210809A2/es not_active Application Discontinuation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100441638B1 (ko) | 2001-01-19 | 2004-07-23 | 주식회사 엘지생명과학 | 새로운 에이사이클릭 뉴클레오사이드 포스포네이트유도체, 그의 염 및 합성 방법 |
US20060052346A1 (en) | 2004-02-17 | 2006-03-09 | Averett Devron R | Nucleoside phosphonate derivatives useful in the treatment of HIV infections |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018016795A1 (ko) * | 2016-07-18 | 2018-01-25 | 일동제약주식회사 | 항바이러스성 약물의 오로트산염, 이의 제조 방법 및 상기 염을 포함하는 약제학적 조성물 |
KR20180009195A (ko) | 2016-07-18 | 2018-01-26 | 일동제약(주) | 항바이러스성 약물의 오로트산염, 이의 제조 방법 및 상기 염을 포함하는 약제학적 조성물 |
KR102623581B1 (ko) | 2016-07-18 | 2024-01-11 | 일동제약(주) | 항바이러스성 약물의 오로트산염, 이의 제조 방법 및 상기 염을 포함하는 약제학적 조성물 |
WO2018164458A1 (ko) * | 2017-03-07 | 2018-09-13 | 일동제약주식회사 | 베시포비르 디피복실 또는 이의 약제학적 허용되는 염 함유 과립, 상기 과립을 포함하는 약제학적 조성물 및 이의 제조 방법 |
KR101899773B1 (ko) * | 2017-03-07 | 2018-09-18 | 일동제약(주) | 베시포비르 디피복실 또는 이의 약제학적 허용되는 염 함유 과립, 상기 과립을 포함하는 약제학적 조성물 및 이의 제조 방법 |
Also Published As
Publication number | Publication date |
---|---|
TWI384986B (zh) | 2013-02-11 |
CL2008000070A1 (es) | 2008-07-25 |
EP2124953A4 (en) | 2011-02-09 |
WO2008088147A1 (en) | 2008-07-24 |
KR20080067969A (ko) | 2008-07-22 |
TW200836744A (en) | 2008-09-16 |
CA2673510C (en) | 2012-08-21 |
BRPI0806461A2 (pt) | 2011-09-06 |
ZA200904378B (en) | 2010-05-26 |
CO6210809A2 (es) | 2010-10-20 |
CN101616674B (zh) | 2012-06-13 |
US20090325904A1 (en) | 2009-12-31 |
EP2124953A1 (en) | 2009-12-02 |
UA91655C2 (ru) | 2010-08-10 |
AR064915A1 (es) | 2009-05-06 |
BRPI0806461B1 (pt) | 2019-09-03 |
JP4980431B2 (ja) | 2012-07-18 |
CA2673510A1 (en) | 2008-07-24 |
CN101616674A (zh) | 2009-12-30 |
MY163479A (en) | 2017-09-15 |
BRPI0806461B8 (pt) | 2021-05-25 |
MX2009006826A (es) | 2009-07-02 |
EA015269B1 (ru) | 2011-06-30 |
JP2010516668A (ja) | 2010-05-20 |
EA200970690A1 (ru) | 2009-12-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108779126B (zh) | 2-[(2s)-1-氮杂双环[2.2.2]辛-2-基]-6-(3-甲基-1h-吡唑-4-基)噻吩并[3,2-d]嘧啶-4(3h)-酮半水合物的结晶形式 | |
US10017513B2 (en) | Crystalline forms of sodium 4-{[9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-pyrimido [5,4-D][2]benzazepin-2-YL]amino}-2-methoxybenzoate | |
KR100935904B1 (ko) | 항바이러스성 약물의 말레산 단일염 및 이를 함유하는약제학적 조성물 | |
JP7100625B2 (ja) | 置換2-h-ピラゾール誘導体の結晶形、塩型及びその製造方法 | |
US8946249B2 (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
JP6139792B2 (ja) | タンキラーゼ阻害剤としてのピリド[2,3−d]ピリミジン−4−オン化合物 | |
EP3176173B1 (en) | Crystalline free bases of c-met inhibitor or crystalline acid salts thereof, and preparation methods and uses thereof | |
CN109311852A (zh) | 作为egfr抑制剂的苯胺嘧啶化合物的结晶 | |
CN100516047C (zh) | 内酰胺化合物 | |
CN113278010A (zh) | 一类蛋白激酶降解剂及其用途 | |
EP3331873B1 (en) | A 4-(3-pyrazolylamino)-benzimidazole derivative as jak1 inhibitor for treating cancer | |
CN114073704A (zh) | 具有大环结构的含氟并杂环衍生物的应用 | |
WO2023093859A1 (zh) | Axl激酶抑制剂的盐、其制备方法和用途 | |
CN116178434A (zh) | Axl激酶抑制剂的单对甲苯磺酸盐及其晶型 | |
CN118302430A (en) | Mono-p-toluene sulfonate and crystal forms of AXL kinase inhibitor | |
CN114728973B (en) | Crystal form of nucleoprotein inhibitor and application thereof | |
CN111943946B (zh) | 含有氮杂环片段的二氢喹嗪酮羧酸类化合物及其应用 | |
EP4361140A1 (en) | Pharmaceutically acceptable salt and crystal form of fused pyridine ring derivative and preparation method therefor | |
CN107337702B (zh) | 结晶型hcv抑制剂及其制备方法和应用 | |
WO2019085860A1 (zh) | Fgfr4抑制剂晶型及其制备方法 | |
TW202340193A (zh) | 吡唑并嘧啶酮類化合物及其鹽的結晶 | |
CN117794934A (zh) | 吡咯并嘧啶类化合物的晶型及其制备方法 | |
CN115703760A (zh) | 2,4-二取代嘧啶类细胞周期蛋白依赖性激酶酶抑制剂及其制备方法和应用 | |
EA043251B1 (ru) | Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение | |
JP2013184934A (ja) | オキサジアゾリジンジオン化合物の新規な塩及びその結晶 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20121011 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20130911 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20140915 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20150924 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20160912 Year of fee payment: 8 |
|
A101 | Application to extend term of patent right by permit | ||
FPAY | Annual fee payment |
Payment date: 20170919 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20181016 Year of fee payment: 10 |